Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Jesse Schold to Disease Progression

This is a "connection" page, showing publications Jesse Schold has written about Disease Progression.

 
Connection Strength
 
 
 
0.296
 
  1. Grams ME, Sang Y, Ballew SH, Matsushita K, Astor BC, Carrero JJ, Chang AR, Inker LA, Kenealy T, Kovesdy CP, Lee BJ, Levin A, Naimark D, Pena MJ, Schold JD, Shalev V, Wetzels JFM, Woodward M, Gansevoort RT, Levey AS, Coresh J. Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data. J Am Soc Nephrol. 2019 09; 30(9):1746-1755.
    View in: PubMed
    Score: 0.101
  2. Cholin L, Ashour T, Mehdi A, Taliercio JJ, Daou R, Arrigain S, Schold JD, Thomas G, Nally J, Nakhoul NL, Nakhoul GN. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression. BMC Nephrol. 2021 07 15; 22(1):264.
    View in: PubMed
    Score: 0.029
  3. Navaneethan SD, Kirwan JP, Remer EM, Schneider E, Addeman B, Arrigain S, Horwitz E, Fink JC, Lash JP, McKenzie CA, Rahman M, Rao PS, Schold JD, Shafi T, Taliercio JJ, Townsend RR, Feldman HI. Adiposity, Physical Function, and Their Associations With Insulin Resistance, Inflammation, and Adipokines in CKD. Am J Kidney Dis. 2021 01; 77(1):44-55.
    View in: PubMed
    Score: 0.027
  4. Azem R, Daou R, Bassil E, Anvari EM, Taliercio JJ, Arrigain S, Schold JD, Vachharajani T, Nally J, Na Khoul GN. Serum magnesium, mortality and disease progression in chronic kidney disease. BMC Nephrol. 2020 02 12; 21(1):49.
    View in: PubMed
    Score: 0.026
  5. Rincon-Choles H, Jolly SE, Arrigain S, Konig V, Schold JD, Nakhoul G, Navaneethan SD, Nally JV, Rothberg MB. Impact of Uric Acid Levels on Kidney Disease Progression. Am J Nephrol. 2017; 46(4):315-322.
    View in: PubMed
    Score: 0.022
  6. Navaneethan SD, Jolly SE, Schold JD, Arrigain S, Nakhoul G, Konig V, Hyland J, Burrucker YK, Dann PD, Tucky BH, Sharp J, Nally JV. Pragmatic Randomized, Controlled Trial of Patient Navigators and Enhanced Personal Health Records in CKD. Clin J Am Soc Nephrol. 2017 Sep 07; 12(9):1418-1427.
    View in: PubMed
    Score: 0.022
  7. Nakhoul GN, Huang H, Arrigain S, Jolly SE, Schold JD, Nally JV, Navaneethan SD. Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease. Am J Nephrol. 2015; 41(6):456-63.
    View in: PubMed
    Score: 0.019
  8. Crews DC, Scialla JJ, Boulware LE, Navaneethan SD, Nally JV, Liu X, Arrigain S, Schold JD, Ephraim PL, Jolly SE, Sozio SM, Michels WM, Miskulin DC, Tangri N, Shafi T, Wu AW, Bandeen-Roche K. Comparative effectiveness of early versus conventional timing of dialysis initiation in advanced CKD. Am J Kidney Dis. 2014 May; 63(5):806-15.
    View in: PubMed
    Score: 0.017
  9. Taliercio JJ, Schold JD, Simon JF, Arrigain S, Tang A, Saab G, Nally JV, Navaneethan SD. Prognostic importance of serum alkaline phosphatase in CKD stages 3-4 in a clinical population. Am J Kidney Dis. 2013 Oct; 62(4):703-10.
    View in: PubMed
    Score: 0.017
  10. Bihorac A, Schold JD, Hobson CE. Acute kidney injury and long-term outcomes: more to learn. Kidney Int. 2010 Apr; 77(8):745; author reply 745.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)